New Astellas, Seattle Genetics Padcev combo data spark $5.8B sales hopes
Astellas and Seattle Genetics impressed Wall Street last fall when their combination of Padcev and Merck’s Keytruda fought off advanced bladder cancer in previously untreated patients. Friday, the partners presented updated results that look even better. They might even be good enough to snag an expedited regulatory review, analysts say—and at least one market-watcher hiked… Read More »